Table 2.
Direct-acting antiviral and antiretroviral scorecard
| HIV therapy | HCV therapy |
|||||
|---|---|---|---|---|---|---|
| Boceprevir | Telaprevir | Simeprevir | Faldaprevir | Daclatasvir | Sofosbuvir | |
| Atazanavir/ritonavir | × | ✓ | No data | No data | ✓* | No data |
|
| ||||||
| Darunavir/ritonavir | × | × | × | ✓ | No data | ✓ |
|
| ||||||
| Fosamprenavir/ritonavir | No data | × | No data | No data | No data | No data |
|
| ||||||
| Lopinavir/ritonavir | × | × | No data | No data | No data | No data |
|
| ||||||
| Nelfinavir | No data | No data | No data | No data | No data | No data |
|
| ||||||
| Efavirenz | × | ✓* | × | ✓* | ✓* | ✓ |
|
| ||||||
| Rilpivirine | ✓ | ? | ✓ | No data | No data | ✓ |
|
| ||||||
| Etravirine | ? | ✓ | No data | No data | No data | No data |
|
| ||||||
| Raltegravir | ✓ | ✓ | ✓ | No data | No data | ✓ |
|
| ||||||
| Elvitegravir/cobicistat | No data | No data | No data | No data | No data | No data |
|
| ||||||
| Maraviroc | ✓* | ✓* | No data | No data | No data | No data |
× indicates the presence of an interaction, ✓ indicates the absence of a clinically important interaction, ✓* indicates that the combination is acceptable, but requires dose adjustment (see main text), ? indicates the presence of an interaction with uncertain clinical importance, ‘No data’ indicates no interaction data are currently available with the combination.